1. Parkinson Disease Psychosis

2. This program may include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. PD and PDP: Overview

4. Recognizing PDP

5. Recognizing PDP (cont)

6. Hallucinations and Delusions: Hallmarks of PDP

7. Are You Seeing Things? Queries for the Patient

8. Steps Before Prescribing an Antipsychotic Patient Assessment

9. Considerations When Prescribing an Antipsychotic

10. Pimavanserin: 5-HT2A Inverse Agonist

11. Improving Collaborative Care

12. Medications Used for PDP

13. FDA Pimavanserin Analysis No New or Unexpected Risks

14. Challenges of PDP Care

15. Monitoring Pimavanserin Use

16. Concluding Remarks

17. Abbreviations